Clinical Trials Indicate In Eczema Treatment - Less Is Best

Drug developer Corgentech Inc. said Monday that the lowest dose of its Avrina eczema treatment proved to be the most effective in an early- to mid-stage clinical trial.
The company achieved the major aim of the trial, which was to show if Avrina was safe and well-tolerated in a range of doses.
However, the company found that the lowest of three tested doses was the most effective in reducing combined eczema symptom scores after 22 days, even though the results were just shy of being statistically significant given the low number of patients observed.